Organon & Co. (NYSE:OGN) Rating Lowered to Hold at BNP Paribas Exane

Key Points

• BNP Paribas Exane downgraded Organon & Co. from "strong-buy" to "hold," and the stock now carries a MarketBeat consensus rating of "Reduce" with a $10.75 consensus price target.
• Sun Pharma submitted a definitive all-cash offer to buy Organon for $14.00 per share (about $11.75 billion), sending the shares to a 52-week high and prompting some brokers to adjust ratings and price targets.
• Several shareholder-law firms have launched investigations into the fairness and process of the $14 offer, creating potential litigation and execution risk that could delay the deal or push for a higher price.

Organon & Co. (NYSE:OGN - Get Free Report) was downgraded by analysts at BNP Paribas Exane from a "strong-buy" rating to a "hold" rating in a research note issued on Tuesday,Zacks.com reports.

A number of other brokerages have also recently commented on OGN. Piper Sandler upgraded shares of Organon & Co. from an "underweight" rating to a "neutral" rating and upped their price target for the company from $5.00 to $14.00 in a research note on Tuesday. Barclays upped their price target on shares of Organon & Co. from $7.50 to $8.00 and gave the company an "underweight" rating in a research note on Tuesday, February 24th. Wall Street Zen cut shares of Organon & Co. from a "buy" rating to a "hold" rating in a research note on Saturday, January 31st. Finally, Zacks Research upgraded shares of Organon & Co. from a "strong sell" rating to a "hold" rating in a research note on Tuesday, April 14th. Four analysts have rated the stock with a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Reduce" and a consensus price target of $10.75.

Organon & Co. Stock Performance

Shares of OGN stock opened at $13.34 on Tuesday. The stock has a market capitalization of $3.50 billion, a P/E ratio of 18.78, a PEG ratio of 1.22 and a beta of 0.67. The company has a current ratio of 1.82, a quick ratio of 1.23 and a debt-to-equity ratio of 11.47. The firm's 50 day moving average is $7.45 and its 200 day moving average is $7.68. Organon & Co. has a 12 month low of $5.69 and a 12 month high of $13.38.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings results on Thursday, February 12th. The company reported $0.63 EPS for the quarter, missing analysts' consensus estimates of $0.73 by ($0.10). The business had revenue of $1.51 billion for the quarter, compared to analysts' expectations of $1.52 billion. Organon & Co. had a net margin of 3.01% and a return on equity of 122.01%. The business's quarterly revenue was down 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 earnings per share. On average, sell-side analysts anticipate that Organon & Co. will post 3.23 earnings per share for the current year.

Institutional Trading of Organon & Co.

Several institutional investors and hedge funds have recently made changes to their positions in OGN. Royal Bank of Canada raised its position in shares of Organon & Co. by 53.4% during the 1st quarter. Royal Bank of Canada now owns 360,862 shares of the company's stock valued at $5,374,000 after buying an additional 125,648 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Organon & Co. by 126.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company's stock valued at $21,370,000 after buying an additional 801,307 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Organon & Co. by 2.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,042,991 shares of the company's stock valued at $15,530,000 after buying an additional 26,640 shares in the last quarter. Focus Partners Wealth raised its position in shares of Organon & Co. by 33.2% during the 1st quarter. Focus Partners Wealth now owns 55,875 shares of the company's stock valued at $832,000 after buying an additional 13,925 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Organon & Co. during the 2nd quarter valued at $107,000. Hedge funds and other institutional investors own 77.43% of the company's stock.

Organon & Co. News Roundup

Here are the key news stories impacting Organon & Co. this week:

• Positive Sentiment: Sun Pharma agreed to buy Organon for $14.00 per share in an all-cash deal valued at $11.75B — a definitive bid that typically sets a takeover floor and caused the stock to rally on the news. Indian drugmaker Sun Pharma to buy U.S. firm Organon in $11.75 billion deal
• Positive Sentiment: Shares hit a 52-week high and saw large intraday volume and elevated call-option buying, signaling strong investor/speculator interest and momentum following the acquisition announcement. Organon Soars to 52-Week High on $11.75-Billion Sun Merger
• Positive Sentiment: Piper Sandler upgraded OGN from underweight to neutral and set a $14 price target (matching the buyout price), which offers analyst support for the deal valuation. Piper Sandler upgrade / price target
• Neutral Sentiment: Coverage and analyst write-ups are discussing strategic rationale (Sun Pharma gaining women’s health, biosimilars and global scale). These narratives help explain the bid but do not change the cash-per-share offer. Why is Sun Pharma betting $11.75B on a struggling US drugmaker?
• Negative Sentiment: Multiple shareholder-law firms (Kahn Swick & Foti, Halper Sadeh, Johnson Fistel, Monteverde/other firms) have launched investigations into the fairness of the $14 offer and the board’s process — these actions can lead to litigation, potential delays, demands for a higher price or complications to closing. Organon Investor Alert: Kahn Swick & Foti investigation
• Negative Sentiment: Other firms (Halper Sadeh, Johnson Fistel, Ademi LLP, M&A Class Action Firm and others) have issued similar alerts alleging potential breaches of fiduciary duty and possible preferential insider benefits or deal protections that could limit competing bids. These raise execution risk for shareholders expecting a clean, quick close. Halper Sadeh investigation

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.